cobas b 101 system
Enhancing patient care at the point of need with combined HbA1c and lipid panel testing
Both diabetes and dyslipidemia are growing in prevalence every year, yet only 50% of people who have either disease are diagnosed. A challenge to global healthcare

By 2012 the number of people living with diabetes reached 371 million worldwide. In this year alone 4.8 million people died as a result of having the disease. If left untreated, increased blood glucose levels may lead to serious complications affecting the heart and blood vessels, eyes, kidneys, and nerves. Type 2 diabetes, characterised by insufficient insulin production or cellular response to it, is the most common type, affecting 90–95% of people with diabetes. Dyslipidemia is a disorder of lipoprotein metabolism that affects over 300 million people worldwide and leads to the development of atherosclerosis and other related diseases. Both diabetes and dyslipidemia are growing in prevalence every year; yet only 50% of people who have either disease are diagnosed.

Major risk factors for CVD

In people aged 50 years and above, diabetes increases the lifetime risk for CVD above that of any other single risk factor. Type 2 diabetes is also considered a coronary heart disease (CHD) risk-equivalent condition, as people with type 2 diabetes have as high a risk for myocardial infarction (MI) as those with previous MI. Similarly, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides are independent risk factors for CVD.

CVD is the leading cause of death globally

In 2010 there were a total of 62.5 million worldwide cases of CHD, congestive heart failure and stroke. By 2030 this number is expected to increase by a third to 83.9 million. More people die annually from CVD than from any other cause. In 2008 there were 17.3 million deaths attributed to CVD. By 2030 deaths from CVD are expected to increase 35% to 23.3 million. In 2010, the global cost of CVD was USD 863 billion and it is estimated to rise to USD 1.044 billion in 2030 – an increase of 22%. Early identification and treatment of CVD risk factors is essential for reducing the global burden of this often deadly disease.
Metabolic syndrome identifies those at high risk of developing CVD and diabetes
Most individuals with CVD have multiple risk factors, of which several are interrelated and cluster together. The presence of multiple risk factors adds substantial CVD risk over and above the sum of the risk associated with each individual risk factor. Around 20–25% of the world’s adults have metabolic syndrome, a term used to describe a group of such risk factors (Fig. 1). People with metabolic syndrome have a three-fold higher risk of heart attack or stroke and a two-fold risk of mortality from these conditions. They also have a five-fold greater risk of developing type 2 diabetes.

Metabolic syndrome Driving a new global CVD epidemic

Glycated hemoglobin (HbA1c) concentrations reflect average glycemia over the preceding 2–3 months. Point-of-care HbA1c and lipid panel testing, in combination with blood pressure and waist circumference measurements, allow physicians to diagnose patients with metabolic syndrome within the timeframe of the consultation. Because many people who are tested for metabolic syndrome are likely to already be affected by diabetes and/or CVD without knowing it, it is important that these individuals are identified early so that lifestyle interventions and/or treatment can be initiated as early as possible to minimise complications.

Optimising management of patients with dyslipidemia at the physician’s office
Point-of-care lipid panel testing has been shown to result in a higher percentage of patients with either total cholesterol or triglyceride levels within the target range, and enhanced medication adherence and treatment satisfaction. Point-of-care lipid panel testing has also been shown to improve cholesterol risk management in high-risk patients, and to improve LDL-C, non-HDL-C and total cholesterol goal attainment. Similarly, physicians performed a higher number of patient risk assessments for CHD when patient results were available during the same office visit, compared with cases where patient results were only available after the office visit (88% vs. 19%).

Supporting early diagnosis of metabolic syndrome at the physician’s office
Glycated hemoglobin (HbA1c) concentrations reflect average glycemia over the preceding 2–3 months. Point-of-care HbA1c and lipid panel testing, in combination with blood pressure and waist circumference measurements, allow physicians to diagnose patients with metabolic syndrome within the timeframe of the consultation. Because many people who are tested for metabolic syndrome are likely to already be affected by diabetes and/or CVD without knowing it, it is important that these individuals are identified early so that lifestyle interventions and/or treatment can be initiated as early as possible to minimise complications.

Figure 1: Clinical components of metabolic syndrome. According to the new International Diabetes Federation (IDF) definition, for a person to be defined as having the metabolic syndrome they must have central obesity plus any two of the other four factors.
In the management of diabetes, HbA1c measurement is the gold-standard for long-term follow-up of glycemic control and is complementary to patient self-monitoring of blood/interstitial glucose.15,16 HbA1c testing has many benefits for patients and their physicians (Table 1).32,33

- HbA1c testing is convenient for the patient
  - Fasting is not required prior to taking sample
  - Sample may be taken at any time of day
  - Minimal preparation required by the patient

- HbA1c test results are reliable
  - Low biological variability
  - High sample stability
  - Reproducible test results
  - Greater pre-analytical stability than glucose
  - Not affected by acute factors (e.g., stress, exercise)

- HbA1c test results are related to the progression of disease complications
  - Reflects long-term glycemic control
  - Better predicts the development of CVD than glucose
  - May identify individuals with greater susceptibility to protein glycation
  - May identify individuals with higher complication rates

Table 1: The benefits of HbA1c testing.32,33

Optimising management of patients with diabetes at the physician’s office

Immediate feedback of HbA1c results can improve patients’ glycemic control (Fig. 2) and increase the percentage of patients within their HbA1c target range.17-20 Rapid availability of HbA1c results also enhances clinical decision making in terms of appropriate intensification of therapy,20-21 improves medication adherence22 and patient satisfaction,19 and may potentially reduce diabetes-related expenses and patient-borne costs (UK-based studies).23,31 Furthermore, patients with diabetes who receive point-of-care testing are more likely to be motivated to look after their condition and to view their relationship with their physician as being strengthened.19

![Graph](graph.png)  
Figure 2: Changes in HbA1c levels (%) from baseline at 6- and 12-month follow-up in point-of-care testing and usual care groups.28 *p < 0.05 vs. baseline.

Point-of-care testing … has the potential to improve monitoring of chronic conditions, therapeutic control and clinical efficiency, and to enhance clinical decision making within the timeframe of the consultation.17

In the management of diabetes, HbA1c measurement is the gold-standard for long-term follow-up of glycemic control and is complementary to patient self-monitoring of blood/interstitial glucose.15,16 HbA1c testing has many benefits for patients and their physicians (Table 1).32,33
The cobas b 101 system can support physicians to optimise the management of patients with diabetes and dyslipidemia, and support the early diagnosis of patients with metabolic syndrome who are at high risk of developing CVD and diabetes.

The cobas b 101 system is a point-of-care device offering combined HbA1c and lipid panel* testing on one platform.

The cobas b 101 system offers single testing (HbA1c or lipid panel, separately) as well as dual testing (HbA1c and lipid panel, consecutively) with fast turnaround time:
- Single HbA1c test result in less than 6 minutes
- Single lipid panel result in approximately 6 minutes
- Dual HbA1c test and lipid panel results in 15 minutes

* Lipid panel testing includes:
- Total cholesterol (measured)
- Triglycerides (measured)
- HDL-C (measured)
- LDL-C (calculated)
- non-HDL-C (calculated)
- Total cholesterol/HDL-C ratio (calculated)

From patient preparation to the display of HbA1c test and lipid panel results in one 15-minute workflow:
1. Simultaneous loading of both discs from a single finger prick
2. Fill lipid disc. Put aside lipid disc (max. 8 min.)
3. Fill HbA1c disc (80 – 90 sec. [max. transfer time])
4. Insert HbA1c disc right away (6 min.)
5. Remove HbA1c disc when test is finished
6. Insert lipid disc (6 min.)
7. cobas HbA1c test and lipid panel results are shown together at the end
Comprehensive connectivity and data management

- Large data storage with 5,000 patient results, 500 external devices such as a printer and a barcode scanner are available
- Easy and safe handling of samples and test discs
- External multicenter studies performed under guidelines have shown that both the cobas Hba1c test and cobas lipids panel met high standards for precision and accuracy derived from the National Glycohemoglobin Standardization Program (NGSP) and National Cholesterol Education Program (NCEP)

**User-friendly, robust and service-free**
- Large touchscreen, full keyboard on display, and multiple language support
- Menus integrate test and graphical guidance for simplified use
- Reference ranges are configurable and individual results comments can be added
- No calibration is needed, samples and discs are checked for integrity, and all steps of the process are controlled
- Quality control menu features configurable test intervals, target ranges and QC lockout

**Confirmed performance with full compliance to guidelines**
- External multicenter studies performed under Clinical and Laboratory Standards Institute (CLSI) guidelines have shown that both the cobas Hba1c test and cobas lipid panel met high standards for precision and accuracy derived from the National Glycohemoglobin Standardization Program (NGSP) and National Cholesterol Education Program (NCEP)

**References**

23. Roche data on file. 34 Roche data on file.
33. Roche data on file.